Tresiba Manufacturer Copay Program: How Women Can Access Insulin Degludec for Less

What Is Tresiba and Why Do Women Specifically Ask About It?

Tresiba is a once-daily ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours in most adults. It covers your background insulin needs without the pronounced peak that older basals like NPH produce, which matters because women with type 1 diabetes experience cyclical insulin-resistance shifts tied directly to their menstrual cycle and hormonal status.

Women make up roughly half of the 34.2 million Americans living with diagnosed diabetes, and they carry a disproportionate cardiovascular risk burden compared to men with the same diagnosis. For women managing type 1 or insulin-requiring type 2 diabetes, choosing the right basal insulin is not a minor administrative decision. It affects glycemic variability across the menstrual cycle, through pregnancy, and into the metabolic shifts of perimenopause.

Tresiba's flat pharmacokinetic profile is one reason clinicians often reach for it. The SWITCH 1 trial, a crossover study in type 1 diabetes, showed that insulin degludec reduced hypoglycemia rates compared to insulin glargine U100, including a 36% reduction in nocturnal confirmed hypoglycemia. That nocturnal hypoglycemia reduction is clinically meaningful for women who are pregnant or breastfeeding, because nighttime lows carry compounding risk in those states.

The barrier, bluntly, is cost. Without any assistance, a single 10 mL vial of Tresiba U100 can run $300 to over $400 at retail pharmacies in the United States. That price has pushed many women to ration doses, a practice documented by the American Diabetes Association to increase risk of diabetic ketoacidosis hospitalizations.

How the Novo Nordisk Tresiba Copay Program Works

The Novo Nordisk My$99Insulin program and the broader Novo Nordisk copay assistance structure are your first stop if you carry commercial insurance. Here is how it works in practice.

Who Qualifies for the Copay Card

To use the Novo Nordisk commercial copay card for Tresiba, you must:

• Have commercial (private) insurance that covers Tresiba
• Be a resident of the United States or its territories
• Not be enrolled in a federal or state government insurance program (Medicare Part D, Medicaid, TRICARE, Veterans Affairs, or any other federal/state payer)

The program cannot be used in combination with any government insurance, even as secondary coverage. This is a federal anti-kickback restriction, not a Novo Nordisk policy quirk.

What the Copay Card Actually Covers

Eligible patients may pay as little as $35 per fill. The manufacturer card covers the gap between your insurance copay and that $35 floor, up to a set annual cap. Annual cap amounts change, so verify the current cap at the point of enrollment. Some years the cap has been $3,600 annually; confirm this has not changed before relying on it.

How to Enroll

1. Visit the Novo Nordisk patient savings page or ask your pharmacist to run the copay card.
2. Download or activate the card digitally. Enrollment is typically instant online.
3. Present the card alongside your insurance card at the pharmacy counter.
4. If the pharmacist says the card "doesn't work," ask them to run it as a third-party processor, not as a secondary insurance plan. Pharmacy staff sometimes input it incorrectly on the first attempt.

A practical note specific to women: if you are newly postpartum and your insurance changed during a special enrollment period after delivery, confirm that your new plan still covers Tresiba on formulary before counting on the $35 price. Formulary status is plan-specific, and postpartum insurance transitions are a common point where coverage gaps emerge.

If You Are Uninsured or Underinsured

Not having commercial insurance does not mean you are out of options. Several pathways exist, and the right one depends on your income, life stage, and how urgently you need insulin.

Novo Nordisk Patient Assistance Program (PAP)

Novo Nordisk offers a Patient Assistance Program for uninsured or underinsured patients who meet income criteria. Through the PAP, qualifying patients can receive Tresiba at no cost or very low cost. The Novo Nordisk PAP requires proof of income, proof of U.S. Residency, and a prescriber signature. Processing typically takes two to six weeks, so do not wait until you are completely out of insulin to apply.

My$99Insulin Program

Novo Nordisk also maintains a program allowing uninsured patients to purchase participating insulins, including Tresiba, for $99 per month regardless of quantity. This is distinct from the commercial copay card. At the time this article was reviewed, the $99 program was active. Verify current availability because Novo Nordisk has adjusted and relaunched these programs multiple times in recent years.

Insulin-Sharing Programs and Emergency Access

Organizations like Mutual Aid Diabetes support community insulin sharing on a need basis. These are not manufacturer programs, and insulin obtained this way has no cold-chain guarantee, but they are a documented emergency safety net used by real patients while longer-term assistance applications are pending.

Compounded Insulin: What Women Should Know

Compounded basal insulins are available through 503B outsourcing facilities. Cost can be dramatically lower, sometimes approaching $0 through specific clinical programs. The trade-off is that compounded insulin is not FDA-approved. There is no published pharmacokinetic equivalence study confirming that compounded insulin degludec behaves identically to brand Tresiba. For women in pregnancy especially, this uncertainty matters clinically. Discuss this explicitly with your clinician before substituting.

Tresiba and the Menstrual Cycle: What Changes and When

Insulin sensitivity in women with type 1 diabetes fluctuates measurably across the menstrual cycle. In the luteal phase (roughly days 15 to 28), rising progesterone increases insulin resistance. Many women require 10 to 20 percent higher basal rates during this window, a pattern documented in research published in Diabetes Care.

Tresiba's flat action profile makes these adjustments more predictable than with NPH or insulin glargine, which have more pronounced peaks. You can titrate Tresiba's dose incrementally without the risk of a peak-related low that comes with older insulins.

Practical guidance:

• Track your glucose pattern across two to three full cycles before assuming you need a permanent dose change.
• Mark the first day of your period in your CGM app or logbook. Many women find their resistance pattern is consistent enough to anticipate.
• Discuss a "luteal phase protocol" with your endocrinologist or diabetes care and education specialist, meaning a pre-set instruction to increase basal by a specific percentage during days 15 to 28.

Women with PCOS who are also insulin resistant may have a blunted or different cycling pattern. PCOS is associated with chronic low-grade insulin resistance independent of cycle phase, and many women with PCOS who require insulin find their sensitivity does not follow the predictable luteal-phase pattern of women without PCOS. Data specifically studying Tresiba in women with PCOS-related insulin-requiring diabetes is limited. This is an evidence gap, and clinical decisions in this group should be individualized.

Tresiba in Perimenopause and Post-Menopause

Estrogen has direct effects on glucose metabolism. Declining estrogen in perimenopause is associated with increasing insulin resistance and worsening glycemic variability, even in women whose A1c was previously stable. Research published in Menopause has linked the menopausal transition to deteriorating glycemic control in women with type 1 diabetes, even without changes in diet or activity.

For women managing diabetes through perimenopause, Tresiba's consistency across a 42-hour action window can reduce the glycemic chaos that comes with erratic estrogen fluctuations. However, dose requirements may trend upward during the perimenopausal transition and then stabilize or even decrease in post-menopause as the hormonal environment settles.

Hot flashes and night sweats can mimic or mask hypoglycemia symptoms. Women in perimenopause and post-menopause should discuss wearing a continuous glucose monitor (CGM) with their clinician, because subjective symptom recognition becomes less reliable during this stage.

Pregnancy, Lactation, and Contraception: What You Must Know Before Using Tresiba

Insulin degludec carries specific considerations for women who are pregnant, planning a pregnancy, or breastfeeding. This section is not optional reading if any of those apply to you.

Pregnancy Safety Data

The FDA eliminated the A/B/C/D/X pregnancy letter categories in 2015 and replaced them with narrative labeling. The current Tresiba prescribing information states that animal reproduction studies with insulin degludec showed no evidence of harm, but available human data are insufficient to establish risk. The ACOG Practice Bulletin on Pregestational Diabetes recommends that women with type 1 diabetes requiring insulin during pregnancy use agents with the most established human safety data.

Human insulin and insulin analogs including insulin lispro and insulin aspart have larger safety datasets in pregnancy than insulin degludec does. Many maternal-fetal medicine specialists and endocrinologists currently recommend switching to NPH or insulin glargine during pregnancy because the data set for those analogs is larger, though glargine itself has debated data. Tresiba is not the first choice in pregnancy in most academic centers at this time.

If you became pregnant while on Tresiba, do not stop your insulin. Uncontrolled hyperglycemia is immediately harmful to a developing pregnancy. Contact your obstetric and diabetes care team immediately to discuss whether to continue or transition.

Lactation Transfer

Insulin does not transfer to breast milk in clinically meaningful amounts. Even if trace insulin degludec enters milk, it would be degraded in the infant's GI tract and not absorbed systemically. The NIH LactMed database does not list insulin as a concern during lactation. You can continue insulin degludec while breastfeeding, but be aware that breastfeeding itself affects insulin sensitivity. Many women with type 1 diabetes require lower basal doses while exclusively breastfeeding due to the glucose cost of milk production.

Contraception Considerations

Tresiba is not a teratogen in the way that some medications (methotrexate, warfarin, isotretinoin) are. Contraception is not mandatory for its use. Optimal preconception glucose control is strongly recommended before attempting pregnancy, because first-trimester hyperglycemia increases the risk of congenital anomalies. The American Diabetes Association Standards of Care recommend an A1c below 6.5 percent before conception when this can be achieved safely.

Tresiba vs. Other Basal Insulins: A Women's-Health Lens

Choosing among basal insulins involves cost, pharmacokinetics, and how each insulin fits your hormonal reality. Here is a practical comparison.

Tresiba vs. Insulin Glargine (Lantus, Basaglar, Toujeo)

Glargine U100 has the largest pregnancy dataset of any basal analog and is often preferred during pregnancy for that reason alone. Glargine U300 (Toujeo) has a flatter profile than U100 but less data in pregnancy. Tresiba's duration exceeds glargine's, which some women find advantageous for forgotten or delayed doses. The DEVOTE trial, a cardiovascular outcomes trial in over 7,600 patients with type 2 diabetes, found degludec non-inferior to glargine on MACE outcomes with a statistically lower rate of severe hypoglycemia. Women-specific subgroup data from DEVOTE are not separately published in a way that changes prescribing, but the overall hypoglycemia benefit holds across sex.

Tresiba vs. NPH

NPH is dramatically cheaper. Through Walmart's ReliOn program, NPH is available over the counter for $25 per vial. NPH has the most human pregnancy data of any basal insulin. The trade-off is its pronounced peak and twice-daily dosing requirement, which increases hypoglycemia risk. NPH is still used in pregnancy precisely because of its safety record, not because it is the easiest insulin to live with.

Insurance Coverage: Getting Tresiba on Your Plan

Formulary Appeals

If your insurer covers a basal insulin but not Tresiba specifically, your prescriber can file a formulary exception or prior authorization. The argument for Tresiba over glargine is clinical: lower nocturnal hypoglycemia rate (as shown in SWITCH 1), flexibility with variable injection timing, and documented A1c equivalence. Women with a history of severe nocturnal hypoglycemia have a stronger medical-necessity case.

Step Therapy Requirements

Many commercial plans require you to fail on a cheaper basal insulin first (usually glargine) before they approve Tresiba. If you have already used glargine and experienced hypoglycemia issues, make sure that history is documented in your chart. Your prescriber needs to reference it explicitly in the prior authorization letter.

ACA Marketplace Plans and Insulin Cost-Sharing

Under the Inflation Reduction Act, insulin cost-sharing caps now apply to Medicare Part D enrollees ($35 per month per covered insulin). This federal cap does not currently extend to commercial plans, though some states have enacted their own caps. Check your state insurance commissioner's website for state-specific insulin cost-sharing rules that may apply independent of the Novo Nordisk copay card.

Who This Is Right For, and Who Should Pause

Women Who Tend to Do Well on Tresiba

• Women with type 1 diabetes who have experienced nocturnal hypoglycemia on glargine or detemir
• Women in perimenopause with unpredictable glycemic variability who need a consistent basal anchor
• Women with variable schedules who cannot always inject at the exact same time daily (Tresiba allows up to 8-hour timing flexibility)
• Women with type 2 diabetes requiring basal insulin who have commercial insurance and qualify for the copay card

Women Who Should Have a Detailed Conversation First

• Women who are pregnant or planning pregnancy in the next six months (discuss whether a better-studied analog is appropriate for this window)
• Women on Medicaid or Medicare who will not benefit from the commercial copay card and need a different access strategy from the start
• Women with PCOS and variable insulin resistance who may need frequent dose adjustments (Tresiba's 3-day accumulation kinetics mean dose changes take several days to fully manifest)
• Women who are breastfeeding and experiencing significant postpartum insulin sensitivity shifts (dose needs can change week to week in early lactation)

Practical Steps to Get Your First Tresiba Fill for Less

1. Confirm your insurance covers Tresiba. Call the member services number on your insurance card and ask specifically whether insulin degludec is on your formulary and at what tier.
2. If covered commercially, enroll in the Novo Nordisk copay card before your first fill, not after. Retroactive application is generally not possible.
3. If not covered, ask your prescriber to file a prior authorization citing your clinical history and the SWITCH 1 hypoglycemia data.
4. If uninsured, apply for the Novo Nordisk PAP at least four to six weeks before you run out of your current insulin.
5. Ask your pharmacist to check GoodRx and similar discount platforms as a price comparison, not as a substitute for manufacturer programs. Some pharmacies can access lower cash prices through discount networks.
6. Verify all program terms directly at novonordisk-us.com because prices and eligibility rules change, and this article reflects the program as understood in early 2026.